Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anesiva has appointed Michael Kranda as its new president, CEO and a member of the board of directors, effective immediately.
Subscribe to our email newsletter
Mr Kranda succeeds John McLaughlin, who resigned as CEO and member of the Anesiva board to pursue other business interests, while remaining a consultant to the company.
Most recently, Mr Kranda was managing director for biotechnology and life science investments at Vulcan. Before that, Mr Kranda was CEO of Oxford GlycoSciences.
Rodney Ferguson, chairman of the board at Anesiva, said: “Michael is the ideal person to lead Anesiva as it transitions from a drug development company to a commercially focused enterprise.”